Antibiotic Prophylaxis of Infective Endocarditis
نویسندگان
چکیده
منابع مشابه
Antibiotic Prophylaxis of Infective Endocarditis
Links between infective endocarditis (IE) and dental and other invasive procedures were first identified in the 1920s, and the use of antibiotic prophylaxis (AP) to prevent IE was first recommended by the American Heart Association in 1955. Recognising the weak evidence to support this practice and the wider risks of anaphylaxis and antibiotic resistance, guidelines in the USA and Europe have b...
متن کاملAntibiotic prophylaxis, body piercing and infective endocarditis.
Infective endocarditis (IE) is associated with a high degree of morbidity and mortality and generally presents in patients with altered and abnormal heart architecture combined with exposure to bacteria through trauma and other potentially high-risk activities, including body piercing. Modern social behaviour has resulted in increased popularity of the practice of body piercing, particularly am...
متن کاملAntibiotic prophylaxis guidelines for infective endocarditis
Since infective endocarditis (IE) is a life-threatening infection, dentists should be aware of antibiotic prophylaxis guidelines. The American Heart Association (AHA) 4 and the British Society for Antimicrobial Chemotherapy (BSAC) 2 have currently updated their recommendations. In general, both guidelines reflect the need to avoid the overuse of antibiotics, which may lead to the development of...
متن کاملProphylaxis for infective endocarditis: antibiotic sensitivity of dental plaque.
The antibiotic sensitivity pattern of bacteria isolated from bacteraemia after dental extraction was compared with that of bacteria isolated from dental plaque samples from the same patient. The results supported the current practice of using penicillin and erythromycin empirically for prophylaxis. The prediction of the most appropriate antibiotic for prophylaxis using dental plaque samples was...
متن کامل[Antibiotic prophylaxis for the prevention of infective endocarditis].
This paper argues that the National Institute for Health and Clinical Excellence should not offer guidance in situations where there is insufficient evidence equipoise about the potential benefit of the treatment in question. This is broadly for two reasons. First, without knowing if the treatment is effective no cost-effectiveness judgement can be logically made. Second, the implementation of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Infectious Disease Reports
سال: 2017
ISSN: 1523-3847,1534-3146
DOI: 10.1007/s11908-017-0564-y